About the Study

Influenza, or the Flu, is a common viral infection that attacks the respiratory system. In the US alone there are over 3 million cases yearly. The flu Is contagious and can cause mild to severe illness and even lead to death. Populations such as young children, older adults, pregnant women, and people with chronic diseases or weak immune systems are at a higher risk of developing serious flu complications.

In recent years, the use of mRNA as the basis for potential vaccine candidates has shown increasing promise. Potential advantages of this platform include accelerated manufacturing, thereby allowing a later decision to be made regarding the strains to be included in the seasonal vaccine, and potentially higher efficacy relative to currently licensed influenza vaccines.

The purpose of this study is to evaluate the safety and immunogenicity of an mRNA vaccine to prevent influenza. The study will last approximately 6 months with 4 visits to our office.

Study-related care is available to participants at no cost and health insurance is not required nor needed. Compensation for time and travel is available for around $500 to those who qualify.


  • 65+
  • No egg allergies
  • Have not received a flu vaccine in the last 6 months
  • Generally healthy
  • *Please note, other conditions may apply